Hikma Pharmaceuticals PLC is buying a range of assets from Bedford Laboratories, the U.S. generic injectables business of Ben Venue Laboratories Inc., including its product portfolio, raw materials – and troubled manufacturing facilities.
Hikma will pay Ben Venue, which is part of Boehringer Ingelheim GMBH, a total of up to $300 million,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?